Format

Send to

Choose Destination
Adv Ther. 2018 Sep;35(9):1438-1451. doi: 10.1007/s12325-018-0738-5. Epub 2018 Jun 26.

Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.

Author information

1
Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA. dimmerj@karmanos.org.
2
Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA. dimmerj@karmanos.org.
3
Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
4
Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA.
5
EpidStat Institute, Ann Arbor, MI, USA.
6
EpidStat Institute, Rockville, MD, USA.
7
Astellas Pharma Inc., Northbrook, IL, USA.
8
Pfizer, Inc., San Francisco, CA, USA.

Abstract

INTRODUCTION:

Bicalutamide (BIC), a non-steroidal anti-androgen, is FDA-indicated for use in combination with a luteinizing hormone-releasing hormone (LHRH) analog for treatment of Stage D2 metastatic carcinoma of the prostate. Lack of consensus exists regarding the clinical benefit of BIC use, either alone or combined use of BIC with an LHRH analog or antagonist (combined androgen blockade or CAB), versus treatment with androgen deprivation therapy (ADT) alone.

METHODS:

The SEER-Medicare database was used to identify prostate cancer patients aged ≥ 66 years diagnosed between 2007 and 2011 and who filled at least one prescription for BIC. Duration of BIC treatment was assessed in relation to ADT use; either alone (monotherapy), as part of CAB only, and as part of CAB followed by monotherapy. Additionally, we assessed use of BIC during or outside a potential testosterone flare prevention period (initiation within 2 months of an LHRH agonist).

RESULTS:

A total of 7521 prostate cancer patients who filled a prescription for BIC were identified. Eighteen percent of the cohort used BIC alone, over half the patients (54%) used BIC as part of CAB and 27% used BIC as part of CAB followed by monotherapy. Among men treated with BIC as part of CAB, 58% received BIC only within the potential flare period.

CONCLUSIONS:

Although there is no FDA indication for BIC use as monotherapy, > 44% of patients in this study used BIC alone or as part of CAB followed by monotherapy. Further research is necessary to understand the outcomes of BIC utilization in these settings, particularly compared with newer second-generation anti-androgens.

FUNDING:

Medivation LLC, a Pfizer company, and Astellas, Pharma, Inc.

KEYWORDS:

Bicalutamide; Non-steroidal anti-androgen; Prostate cancer; Treatment patterns

PMID:
29946798
PMCID:
PMC6133134
DOI:
10.1007/s12325-018-0738-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center